Personalis Inc PSNL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/02/24 EDT
1.60UNCH (UNCH)
Volume
331,238
52 week range
0.89 - 2.60
Loading...
  • Open1.57
  • Day High1.62
  • Day Low1.51
  • Prev Close1.60
  • 52 Week High2.60
  • 52 Week High Date06/06/23
  • 52 Week Low0.89
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap81.936M
  • Shares Out51.21M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta1.90
  • YTD % Change-23.81

KEY STATS

  • Open1.57
  • Day High1.62
  • Day Low1.51
  • Prev Close1.60
  • 52 Week High2.60
  • 52 Week High Date06/06/23
  • 52 Week Low0.89
  • 52 Week Low Date11/10/23
  • Market Cap81.936M
  • Shares Out51.21M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta1.90
  • YTD % Change-23.81

RATIOS/PROFITABILITY

  • EPS (TTM)-2.25
  • P/E (TTM)-0.71
  • Fwd P/E (NTM)-1.01
  • EBITDA (TTM)-84.938M
  • ROE (TTM)-62.31%
  • Revenue (TTM)73.481M
  • Gross Margin (TTM)24.78%
  • Net Margin (TTM)-147.38%
  • Debt To Equity (MRQ)2.22%

EVENTS

  • Earnings Date05/08/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Personalis Inc

 

Profile

MORE
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of...
Karin Eastham CPA
Independent Chairman of the Board
Christopher Hall
President, Chief Executive Officer, Director
Aaron Tachibana
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Richard Chen M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Stephen Moore
Vice President, General Counsel, Corporate Secretary
Address
6600 Dumbarton Circle
Fremont, CA
94555
United States

Top Peers

SYMBOLLASTCHG%CHG
CDTX
Cidara Therapeutics Inc
12.68UNCHUNCH
HLTH
Cue Health Inc
0.14UNCHUNCH
FBIO
Fortress Biotech Inc
1.80UNCHUNCH
RDHL
Redhill Biopharma Ltd
0.4507UNCHUNCH
SRNE
Sorrento Therapeutics Inc
0.014-0.001-6.6667%